

Table of contents

General comments	i
Preamble	ii
Table of contents	iii
List of abbreviations	vi
1 The Institute for Quality and Efficiency in Health Care	1
1.1 Legal responsibilities	1
1.2 Structure	3
1.3 Evidence-based medicine	6
1.3.1 <i>Practical evidence-based medicine</i>	7
1.3.2 <i>Strategies of evidence-based medicine</i>	7
1.3.3 <i>The relevance of evidence-based medicine for the Institute</i>	8
1.3.4 <i>Evidence-based decision-making in health care</i>	8
1.3.5 <i>The relevance of certainty of results</i>	9
1.3.6 <i>The connection between certainty of results and proximity to everyday conditions</i>	10
2 The Institute's products	13
2.1 Product-specific procedures	13
2.1.1 <i>Reports</i>	14
2.1.2 <i>Rapid reports</i>	19
2.1.3 <i>Health information</i>	21
2.1.4 <i>Working papers</i>	25
2.2 General aspects of the preparation of products	27
2.2.1 <i>Choice of external experts</i>	27
2.2.2 <i>Guarantee of scientific independence</i>	28
2.2.3 <i>Review of the Institute's products</i>	29
2.2.4 <i>Publication of the Institute's products</i>	30
3 Assessment of the benefit and harm of medical interventions	31
3.1 Patient-relevant medical benefit	31
3.1.1 <i>Definition of a patient-relevant medical benefit</i>	31
3.1.2 <i>Surrogates of a patient-relevant medical benefit</i>	33
3.1.3 <i>Assessment of the harm potential of medical interventions</i>	34
3.1.4 <i>Summarising assessment</i>	36
3.2 Specific aspects of the benefit assessment	38
3.2.1 <i>(Un)certainly of results</i>	38
3.2.2 <i>Dramatic effect</i>	39
3.2.3 <i>Study duration</i>	39
3.2.4 <i>Patient-reported outcomes</i>	40
3.2.5 <i>Benefit in small populations</i>	41
3.2.6 <i>Benefit in individual cases</i>	41
3.3 Benefit assessment of drugs	42
3.3.1 <i>Relevance of the drug approval status</i>	43
3.3.2 <i>Studies on the benefit assessment of drugs</i>	44
3.4 Non-drug therapeutic interventions	45

